Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Clinical Immunology · Immunodeficiency 99

The Biology of IMD99: Antibodies and Autoimmunity

At a Glance

IMD99 is a genetic immune disorder in which the body may make too few protective antibodies while also attacking its own blood cells. Problems with B-cell development and T-cell control can therefore lead to infections and autoimmune cytopenias, including anemia or low platelets.

In a typical immune system, there is a careful balance between “defense” and “restraint.” Your body must be aggressive enough to kill germs but restrained enough to leave your own cells alone. In complex immune dysregulation like Immunodeficiency 99 (IMD99), the genetic instructions for this balance are disrupted. This leads to a biological paradox: your immune system is underactive when facing outside threats but overactive when looking at your own body [1][2].

To understand how this happens, we have to look at the specialized roles of B cells and T cells and how a single genetic error can break both functions.

The Dual Role of B Cells

B cells are the “factory” cells of your immune system. Their main job is to produce antibodies (immunoglobulins). In many forms of immune dysregulation, this factory can become stuck in an early, immature stage [3].

  • The Antibody Failure (Underactivity): To make high-quality antibodies that can “remember” a virus, B cells must go through a process called class switching. In complex immunodeficiencies, B cells may fail to mature into “switched memory B cells” or “plasmablasts” [4][5]. This results in hypogammaglobulinemia—a shortage of the antibodies (like IgG) needed to prevent infections [6].
  • The Confused Antibody (Overactivity): Even though the B cells aren’t making enough “good” antibodies to fight germs, they may still produce “bad” antibodies that target your own blood cells [7]. These autoreactive cells are supposed to be weeded out by the body, but in immune dysregulation, the “weeding” process often fails [8].

The T-Cell “Security Guard” Problem

If B cells are the factories, T cells are the managers and security guards. They tell the B cells when to work and when to stop.

  • Helper T Cells: These cells normally guide B cells to make the right antibodies. In immune dysregulation, these signals can become “skewed.” Instead of helpful guidance, they may provide signals that promote inflammation and self-attack [7][9].
  • Regulatory T Cells (Tregs): These are the “peacekeepers.” Their job is to shut down the immune response once a threat is gone and prevent attacks on the body’s own tissues [10]. In conditions like immune dysregulation, these peacekeepers are often too few in number or don’t work correctly, leaving the “aggressive” parts of the immune system unchecked [11][9].

The Logic of Immune Dysregulation

It is helpful to think of complex immune dysregulation not just as a “weak” immune system, but as a dysregulated one. In a “simple” antibody deficiency, the system is just missing a part. In a complex immune dysregulation, the entire communication network is broken [2].

The genetic defect acts like a glitch in a computer’s operating system. This glitch causes two specific failures:

  1. Failure of Host Defense: The system cannot mount an organized attack against bacteria or viruses [8].
  2. Failure of Immune Tolerance: The system “forgets” how to recognize its own cells as friends. This leads to autoimmune cytopenias, where the immune system destroys its own red blood cells (anemia) or platelets (thrombocytopenia) [8][1].

Why Genetics Matter

The specific gene involved in an IEI affects the pathways that both B and T cells use to “talk” to each other. For example, pathways like NF-κB or PI3K are essential for B cells to mature AND for the immune system to maintain peace [12][13]. These are examples of pathways that apply to selected IEIs; your exact mechanism depends on your confirmed genetic report. When these pathways are broken, you get the dual presentation of low antibodies and self-attack.

Distinguishing this from a general immunodeficiency is important because it changes how you and your doctors approach treatment. You aren’t just trying to “boost” the system; you are trying to rebalance it [14]. This often requires a delicate combination of replacing what is missing (antibodies) while carefully quieting the parts that are overactive [14][15].

Common questions in this guide

Why can IMD99 cause both infections and autoimmune blood problems?
IMD99 can weaken host defense because B cells may not mature normally or make enough protective antibodies. At the same time, immune-control systems may fail to remove or restrain cells that react against the body, so red blood cells or platelets can be attacked.
How does IMD99 lead to low antibody levels?
B cells need to mature and change the type of antibody they produce so they can provide strong, lasting protection. In IMD99, this process may be impaired, leaving too few effective memory B cells or antibody-producing cells and lowering immunoglobulins such as IgG.
What causes autoimmune cytopenias in IMD99?
Autoimmune cytopenias occur when immune responses target the body's own blood cells. B cells may make self-reactive antibodies, while poorly controlled T-cell responses may add inflammation; the result can include anemia from red-cell loss or thrombocytopenia from platelet loss.
Why does the exact IMD99 genetic result matter?
The affected gene may change signaling pathways used by B cells, T cells, and immune-control cells. Knowing the confirmed genetic cause can help clinicians understand the pattern of antibody deficiency and autoimmunity and consider the most appropriate monitoring or targeted treatment.
How might IMD99 treatment address both low antibodies and autoimmunity?
Management may need to replace missing antibodies while calming the immune activity that attacks the body's cells. Depending on the genetic cause and clinical findings, clinicians may consider immunoglobulin replacement and immune-modulating treatment; the specific plan must be individualized.

Get notified when new evidence is published on immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    Primary Immunodeficiency in Children With Autoimmune Cytopenias: Retrospective 154-Patient Cohort.

    Westermann-Clark E, Meehan CA, Meyer AK, et al.

    Frontiers in immunology 2021; (12()):649182 doi:10.3389/fimmu.2021.649182.

    PMID: 33968040
  2. 2

    Hematopoietic stem cell transplantation for CTLA-4 insufficiency across Europe: A European Society for Blood and Marrow Transplantation Inborn Errors Working Party study.

    Tsilifis C, Speckmann C, Lum SH, et al.

    The Journal of allergy and clinical immunology 2024; (154(6)):1534-1544 doi:10.1016/j.jaci.2024.08.020.

    PMID: 39218359
  3. 3

    The role of toll-like receptors in B-cell development and immunopathogenesis of common variable immunodeficiency.

    Sharifi L, Mirshafiey A, Rezaei N, et al.

    Expert review of clinical immunology 2016; (12(2)):195-207 doi:10.1586/1744666X.2016.1114885.

    PMID: 26654573
  4. 4

    Murine LRBA deficiency causes CTLA-4 deficiency in Tregs without progression to immune dysregulation.

    Burnett DL, Parish IA, Masle-Farquhar E, et al.

    Immunology and cell biology 2017; (95(9)):775-788 doi:10.1038/icb.2017.50.

    PMID: 28611475
  5. 5

    Common variable immunodeficiency and autoimmune diseases: A 10-year single-center experience.

    Sadi Aykan F, Çölkesen F, Evcen R, et al.

    Archives of rheumatology 2024; (39(4)):588-597 doi:10.46497/ArchRheumatol.2024.10729.

    PMID: 40060126
  6. 6

    Immunoglobulin replacement therapy in primary and secondary antibody deficiency: The correct clinical approach.

    Pecoraro A, Crescenzi L, Granata F, et al.

    International immunopharmacology 2017; (52()):136-142 doi:10.1016/j.intimp.2017.09.005.

    PMID: 28898770
  7. 7

    Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses.

    Romberg N, Le Coz C, Glauzy S, et al.

    The Journal of allergy and clinical immunology 2019; (143(1)):258-265 doi:10.1016/j.jaci.2018.06.012.

    PMID: 29935219
  8. 8

    Intrathymic T-cell ontogeny: Crossroad between immune competence and tolerance.

    Giardino G, Romano R, Grilli L, et al.

    The Journal of allergy and clinical immunology 2025; (156(6)):1489-1499 doi:10.1016/j.jaci.2025.10.007.

    PMID: 41138923
  9. 9

    The TH1 phenotype of follicular helper T cells indicates an IFN-γ-associated immune dysregulation in patients with CD21low common variable immunodeficiency.

    Unger S, Seidl M, van Schouwenburg P, et al.

    The Journal of allergy and clinical immunology 2018; (141(2)):730-740 doi:10.1016/j.jaci.2017.04.041.

    PMID: 28554560
  10. 10

    Immune Checkpoint Dysfunction Remodels Adaptive Immune Receptor Repertoires in CTLA-4 Insufficiency and LRBA Deficiency.

    Cildir G, Cildir S, Erdogan RK, et al.

    Clinical reviews in allergy & immunology 2026; (69(1)).

    PMID: 42895678
  11. 11

    Autoimmunity and its association with regulatory T cells and B cell subsets in patients with common variable immunodeficiency.

    Azizi G, Abolhassani H, Kiaee F, et al.

    Allergologia et immunopathologia 2018; (46(2)):127-135 doi:10.1016/j.aller.2017.04.004.

    PMID: 28735808
  12. 12

    Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans.

    Tuijnenburg P, Lango Allen H, Burns SO, et al.

    The Journal of allergy and clinical immunology 2018; (142(4)):1285-1296 doi:10.1016/j.jaci.2018.01.039.

    PMID: 29477724
  13. 13

    ANCA vasculitis expands the spectrum of autoimmune manifestations of activated PI3 kinase δ syndrome.

    Sood AK, Francis O, Schworer SA, et al.

    Frontiers in pediatrics 2023; (11()):1179788 doi:10.3389/fped.2023.1179788.

    PMID: 37274825
  14. 14

    Inborn errors of immunity (primary immunodeficiencies).

    Kim VHD, Upton JEM, Derfalvi B, et al.

    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2025; (20(Suppl 3)):76 doi:10.1186/s13223-024-00938-z.

    PMID: 39780212
  15. 15

    Inborn Errors of Immunity With Immune Dysregulation: From Bench to Bedside.

    Delmonte OM, Castagnoli R, Calzoni E, Notarangelo LD

    Frontiers in pediatrics 2019; (7()):353 doi:10.3389/fped.2019.00353.

    PMID: 31508401

This page is for informational purposes only and does not constitute medical advice. Your clinical immunologist and hematologist are the best sources for interpreting your genetic results, blood counts, and treatment options.